Lung - Cancer
This article reviews recent efforts to evaluate the use of osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in the neoadjuvant setting for patients with resectable EGFR-mutant non-small cell lung cancer (NSCLC). While adjuvant osimertinib...
This case report describes a 75-year-old patient with a centrally located squamous cell carcinoma extending from the carina to the right intermediate bronchus and the superior segment of the lower...
This Society of Thoracic Surgeons General Thoracic Surgery Database analysis found that postoperative chylothorax risk increases with the extent of lymph-node dissection during pulmonary resection. Although uncommon, chylothorax was associated...
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Taj Mohammed Fiyaz Chowdhry, a consultant thoracic surgeon at Burjeel Specialty Hospital, Sharjah, UAE, about uniportal robotics in the...
High tumor mutational burden (TMB) predicts not only response to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) but also immune-related toxicity. In this single-center cohort of...
